Ivars Kalviņš
| Ivars Kalviņš | |
|---|---|
| Born |
2 June 1947 Riga, Latvian SSR, Soviet Union |
| Nationality | Latvian |
| Fields | Chemistry |
| Institutions | Latvian Institute of Organic Synthesis |
| Alma mater | University of Latvia |
| Known for | meldonium |
Ivars Kalviņš (born June 2, 1947 in Riga) is a Soviet and Latvian chemist and the inventor of meldonium, trade-named Mildronat.[1][2]
He graduated from the Faculty of Chemistry, University of Latvia (1969).[1]
In 1985, Kalviņš defended his thesis at the Leningrad University for the degree of Doctor of Science. Since 1986, he has been working at the Riga Institute of Organic Synthesis. Between 2003-2014, he was the institute's director.
Throughout 1994-2000, Kalviņš was President of the Latvian Society of Chemistry.
Under the leadership of Ivars Kalviņš, a number of drugs were synthesized, including cardioprotector mildronat (meldonium), immunomodulator leakadin, dissociative neramexane. He is the co-author of anticancer drug Belinostat.[3]
Laureate of the State Prize of the Latvian SSR (1988). Full member of the Latvian Academy of Sciences (1994), winner of the Grand Medal, Academy of Sciences of Latvia (2009). Officer of Order of the Three Stars.[4] He was nominated as a finalist for the European Inventor Award 2015.[5]
References
- 1 2 Страница Калвиньша на сайте «Латвийские изобретатели»
- ↑ Biography
- ↑ Тезисы конференции Inovācijas Latvijā — mīts vai realitāte?
- ↑ Иварс Калвиньш: мы фанатики, и этим всё сказано // Latvijas Radio 4
- ↑ "European Inventor Award: Can a British inventor win in the 'Oscars of Innovation'?". The Independent. Retrieved 2016-03-10.
External links
|